Christos Papageorgiou,Angeliki Andrikopoulou,Meletios-Athanasios Dimopoulos,Flora Zagouri
Abstract:Novel chemotherapeutic agents have marked a new era in oncology during the past decade, prolonging significantly the overall survival of breast cancer patients. Nevertheless, contemporary antineoplastic treatments can frequently cause adverse cardiovascular side effects. Common manifestations of chemotherapy-induced cardiotoxicity include cardiomyopathy, ischemia, conduction disturbances, hypertension and thromboembolic events, while the type of the treatment regimen administered crucially determines clinical outcome. The aim of this literature review is to analyze the incidence and the underlying mechanisms of cardiovascular toxicity caused by agents approved for breast cancer, as well as to describe ways of monitoring and treating the cardiotoxic effects in breast cancer patients. Moreover, our work intends to provide an easy-to-grasp synopsis of recent and clinically meaningful advances in the field.
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the issue of cardiovascular toxicity in breast cancer treatment. Specifically, the article aims to analyze and summarize the incidence of cardiovascular toxicity caused by drugs already approved for breast cancer treatment and their underlying mechanisms, and to describe the methods for monitoring and managing these cardiovascular toxicities.
### 1. Research Background
In recent years, new chemotherapy drugs have significantly prolonged the overall survival time of breast cancer patients, but these anti - tumor treatments are often accompanied by serious cardiovascular side effects. Common chemotherapy - induced cardiovascular toxicity manifestations include cardiomyopathy, ischemia, conduction disorders, hypertension, and thromboembolic events. The choice of different treatment regimens has an important impact on clinical outcomes.
### 2. Classification and Mechanisms of Cardiovascular Toxicity
Cardiovascular toxicity is mainly divided into two categories:
- **Irreversible Myocardial Cell Damage (Type I)**: Commonly seen in anthracycline drugs (such as doxorubicin) and cyclophosphamide.
- **Reversible Heart Damage (Type II)**: Usually caused by anti - HER2 drugs (such as trastuzumab) and anti - VEGF drugs, involving mitochondrial and protein dysfunction and impaired cell contractility.
The pathophysiological mechanisms include:
1. Direct cell toxicity
2. Ischemic imbalance in myocardial cells
3. Arrhythmia (caused by myocardial fibrosis or ion channel dysfunction)
4. Myocardial inflammation and pericardial effusion
5. Hypertension
### 3. Cardiovascular Toxicity of Specific Drugs
#### Anthracyclines
- **Representative Drugs**: Doxorubicin, Epirubicin
- **Common Side Effects**: Arrhythmia, asymptomatic left ventricular dysfunction, heart failure, etc.
- **Acute Manifestations**: ECG changes (ST - segment deviation and repolarization abnormalities)
- **Dose - related Toxicity**: Toxicity increases when the cumulative dose is above 400 mg/m².
#### Taxanes
- **Representative Drugs**: Paclitaxel, Docetaxel
- **Main Mechanism**: By releasing a large amount of histamine and stimulating histamine receptors in cardiac tissue, resulting in arrhythmia, conduction disorders, or myocardial ischemia
- **Common Side Effects**: Sinus bradycardia
#### Fluorouracil - based Drugs (5 - FU/Capecitabine)
- **Representative Drugs**: Fluorouracil (5 - FU), Capecitabine
- **Main Mechanism**: Coronary artery spasm and endothelial injury
- **Common Side Effects**: Chest pain, arrhythmia, hypotension, dyspnea, or myocardial infarction
#### Anti - HER2 Therapy
- **Representative Drugs**: Trastuzumab, Lapatinib, Pertuzumab, T - DM1 (Trastuzumab emtansine)
- **Main Mechanism**: Partially recovered heart function damage (Type II), especially with an increased risk when used in combination with anthracycline drugs
- **Common Side Effects**: Decrease in left ventricular ejection fraction (LVEF), heart failure
### 4. Monitoring and Management
In order to effectively manage and prevent cardiovascular toxicity, the following measures are recommended:
- Regularly assess left ventricular function (such as measuring ejection fraction and speckle - tracking imaging)
- Closely monitor the patient's cardiovascular health status, especially when using high - risk drugs
- Adjust the drug dose or select an alternative treatment regimen according to individual circumstances
- Use drugs such as ACE inhibitors or β - blockers for prevention and treatment.
Through the above measures, the cardiovascular health of breast cancer patients can be better protected, their quality of life can be improved, and their survival time can be prolonged.